Capricor Therapeutics, Inc. (CAPR)
34.59
-0.45
(-1.28%)
USD |
NASDAQ |
Apr 16, 16:00
34.26
-0.33
(-0.95%)
After-Hours: 20:00
Capricor Therapeutics Research and Development Expense (Quarterly) : 22.88M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 9.921M |
| Vaxart, Inc. | 45.15M |
| Allogene Therapeutics, Inc. | 25.58M |
| REGENXBIO, Inc. | 55.74M |
| Replimune Group, Inc. | 52.87M |